Abstract 742P
Background
Although most pts with AOC respond to first-line (1L) treatment, >70% experience disease progression (PD) within 2 y. The study assessed if the number of RFs impacts time to PD and overall survival (OS) among pts with OC.
Methods
This retrospective cohort study included pts diagnosed with OC between Jan 1, 2011, and Feb 28, 2021, from the Flatiron Health electronic health record–derived de-identified US database. Pts ≥18 y old, with stage III or IV disease, who initiated 1L platinum-based chemo, had ECOG score of 0 or 1, and ≥12 weeks of follow-up time after 1L treatment were included. Pts were followed from end of 1L treatment (index date [ID]) until last activity or end of study period. Pts were classified as moderate risk (stage III disease, no visible residual disease [nVRD], primary debulking surgery, and BRCA mutant) or high risk (≥1 RF: stage IV disease, VRD, interval debulking surgery [IDS] or no surgery [Sx], and BRCA wild type [wt] or unknown [unk] status). High-risk pts were further grouped by number of RFs. KM methodology was used to estimate the time to next treatment (TTNT), defined as time from ID to start of 2L treatment, death, or last activity; and OS, defined as time from ID to death or last activity.
Results
In total, 1251 pts with AOC were included. 4% (n=50) were moderate risk (0 RFs). 96% (n=1201) were high risk: 24% (n=300) had 1 RF (217 BRCAwt/unk, 56 VRD, 1 stage IV, 26 IDS/no Sx); 35% (n=437) had 2 RFs (373 BRCAwt/unk, 249 VRD, 79 stage IV, 173 IDS/no Sx); 22% (n=274) had 3 RFs (253 BRCAwt/unk, 189 VRD, 150 stage IV, 230 IDS/no Sx); and 15% (n=190) had all 4 RFs. TTNT and OS decreased with more RFs (Table).
Conclusions
These RW analyses demonstrate a decrease in TTNT and OS by the cumulative number of RFs. If validated, number of RFs could be a stratification factor for future 1L OC trials. Table: 742P
| Parameter, median (95% CI) | Overall N=1251 | Total number of RFs | ||||
| 0 N=50 (4%) | 1 N=300 (24%) | 2 N=437 (35%) | 3 N=274 (22%) | 4 N=190 (15%) | ||
| TTNT, mo OS, mo | 10.1 (9.0–11.0) 40.9 (38.4–44.2) | 28.8 (16.4–47.8) 87.8 (53.8–87.8) | 17.9 (14.1–23.5) 69.7 (53.7–not reached) | 11.7 (9.9–13.2) 42.1 (38.4–47.9) | 6.9 (6.0–8.0) 32.3 (28.9–37.1) | 4.8 (4.1–6.2) 19.4 (17.6–23.2) |
Clinical trial identification
Editorial acknowledgement
Medical writing and editorial support, funded by GlaxoSmithKline (Waltham, MA, USA) and coordinated by Johanna Bruneau, PhD, of GlaxoSmithKline, was provided by Nicole Renner, PhD, and Jennifer Robertson, PhD, of Ashfield MedComms, an Ashfield Health company (Middletown, CT, USA).
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline.
Disclosure
D. Chase: Financial Interests, Personal, Speaker’s Bureau: GlaxoSmithKline, AstraZeneca, Takeda, Clovis, Roche, and Merck. J. Perhanidis: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. D. Gupta: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. L. Kalilani: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. S. Lechpammer: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. T. Woodward: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. A. González-Martín: Financial Interests, Personal, Advisory Role: from Amgen, AstraZeneca, Clovis Oncology, Genmab, Mersana, Roche, MSD, Immunogen, Sotio, and Takeda; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Clovis, GlaxoSmithKline, Roche, and MSD; Financial Interests, Institutional, Funding: Roche and GlaxoSmithKline; Non-Financial Interests, Personal, Other, Travel support: GlaxoSmithKline, AstraZeneca and Roche.